Navigation Links
Cardium to Present at 10th Annual Biotech in Europe Investor Forum
Date:9/20/2010

SAN DIEGO, Sept. 20 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at the 10th Annual Biotech in Europe Investor Forum to be held September 29-30, 2010 at the Radisson Blu Hotel in Zurich.  Although this presentation will not be webcast, investors can access a replay of the Company's recent presentation at the Rodman & Renshaw 12th Annual Healthcare Investment Conference at http://www.wsw.com/webcast/rrshq18/cxm/ or at the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar.  

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium lifestyle medicinals brand platform.  The Company's lead product candidates include: (1) Excellagen™ topical gel, for wound care management, which Cardium plans to market launch in the fourth quarter subject to pending FDA 510(k) clearance; and (2) Generx®, a DNA-based angiogenic cardiovascular biologic for patients in international markets with coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.

Copyright 2010 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™ Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.

Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, Appexium™ and Linee™ are trademarks of Tissue Repair Company.


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Regains Listing Compliance With NYSE Amex
2. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
3. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
4. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
5. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
6. Cardium Completes $6.0 Million Registered Direct Offering
7. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
8. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
9. Cardium Regains Listing Compliance with NYSE Amex
10. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
11. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 25, 2017 , ... Provia ... are necessary in the preparation and development of human cells and tissues for ... the US Food and Drug Administration’s (FDA) Current Good Manufacturing Practices (cGMP) guidelines ...
(Date:7/26/2017)... 2017  Nurse practitioners play a crucial role in helping ... Merck Manuals survey released today. The survey of ... most (88 percent) believe they spend at least half of ... ... Merck Manuals survey of 210 nurse practitioners finds that 78% ...
(Date:7/24/2017)... Intralytix, Inc. announced that it received $17.5 ... family group. This investment marks the beginning of a ... bacteriophage-based products, for various benefits in human health and ... As a global key player ... innovative solutions for baking, food taste & pleasure, health ...
(Date:7/20/2017)... ... July 20, 2017 , ... Dr. Asher Kimchi, Founder ... recipients of the 2017 IAC Awards at the 22nd World Congress on Heart Disease ... named four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together ...
Breaking Biology Technology:
(Date:6/30/2017)... 2017 Today, American Trucking Associations announced ... face and eye tracking software, became the newest ... "Artificial intelligence and advanced sensing ... a driver,s attentiveness levels while on the road.  ... detect fatigue and prevent potential accidents, which could ...
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
Breaking Biology News(10 mins):